cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
United Therapeutics Corporation
10 own
10 watching
Current Price
$0
$-0.64
(-0.25%)
logo-uthr
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
11,845.95M
52-Week High
52-Week High
283.09
52-Week Low
52-Week Low
158.38
Average Volume
Average Volume
0.42M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
20.825
iconMarket Capitalization11,845.95M
icon52-Week High283.09
icon52-Week Low158.38
iconAverage Volume0.42M
iconDividend Yield--
iconP/E Ratio20.825
What does the United Therapeutics Corporation do?
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops RemoSynch and RemUnity delivery systems for intravenous and subcutaneous Remodulin; esuberaprost and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Read More
How much money does United Therapeutics Corporation make?
News & Events about United Therapeutics Corporation.
Ticker Report
1day ago
United Therapeutics Co. (NASDAQ:UTHR Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the companys stock in a transaction on Friday, January 27th. The stock was sold at an average price of $260.01, for a total transaction of $2,080,080.00. Following the completion of the ...
Zolmax
1day ago
United Therapeutics Co. (NASDAQ:UTHR Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the businesss stock in a transaction dated Friday, January 27th. The stock was sold at an average price of $260.01, for a total value of $2,080,080.00. Following the transaction, the chief executive ...
Zolmax
4days ago
United Therapeutics Co. (NASDAQ:UTHR Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the stock in a transaction that occurred on Wednesday, January 25th. The stock was sold at an average price of $264.21, for a total value of $2,113,680.00. Following the transaction, the chief executive ...
Ticker Report
7days ago
United Therapeutics Co. (NASDAQ:UTHR Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the companys stock in a transaction on Monday, January 23rd. The stock was sold at an average price of $258.97, for a total value of $2,071,760.00. Following the transaction, the chief ...
Ticker Report
10days ago
United Therapeutics Co. (NASDAQ:UTHR Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the businesss stock in a transaction dated Thursday, January 19th. The stock was sold at an average price of $259.60, for a total value of $2,076,800.00. Following the completion of the sale...
Frequently Asked Questions
Frequently Asked Questions
What is United Therapeutics Corporation share price today?
plus_minus_icon
Can Indians buy United Therapeutics Corporation shares?
plus_minus_icon
How can I buy United Therapeutics Corporation shares from India?
plus_minus_icon
Can Fractional shares of United Therapeutics Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in United Therapeutics Corporation stocks?
plus_minus_icon
What is today’s traded volume of United Therapeutics Corporation?
plus_minus_icon
What is today’s market capitalisation of United Therapeutics Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of United Therapeutics Corporation?
plus_minus_icon
What percentage is United Therapeutics Corporation down from its 52-Week High?
plus_minus_icon
What percentage is United Therapeutics Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.64
(-0.25%)
logo-uthr
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00